CAJ | 학술논문

目的探讨蛋白酪氨酸激酶抑制剂(TKI)导致肿瘤患者肝毒性风险.方法通过PubMed、CNKI、CBM、万方数据库及Google、百度等搜索引擎检索有关.使用TKI治疗各种肿瘤的病例对照研究的文献,评估其发生肝毒性的风险.结果符合纳入标准的文献共有6篇,Meta分析结果发现,与安慰剂组比较, TKI组患者发生肝毒性的风险显著升高,合并效应量OR值为6.07,95%CI为3.06~12.05;以AST升高为观察指数,通过合并分析后发现,使用酪氨酸激酶抑制剂的患者发生肝毒性的风险显著升高,OR值为6.84,95%CI为2.87~16.28.结论肿瘤患者在使用TKI时发生肝毒性的风险明显升高,提示在临床治疗时,需要对患者的肝功能进行实时检测和观察.
목적탐토단백락안산격매억제제(TKI)도치종류환자간독성풍험.방법통과PubMed、CNKI、CBM、만방수거고급Google、백도등수색인경검색유관.사용TKI치료각충종류적병례대조연구적문헌,평고기발생간독성적풍험.결과부합납입표준적문헌공유6편,Meta분석결과발현,여안위제조비교, TKI조환자발생간독성적풍험현저승고,합병효응량OR치위6.07,95%CI위3.06~12.05;이AST승고위관찰지수,통과합병분석후발현,사용락안산격매억제제적환자발생간독성적풍험현저승고,OR치위6.84,95%CI위2.87~16.28.결론종류환자재사용TKI시발생간독성적풍험명현승고,제시재림상치료시,수요대환자적간공능진행실시검측화관찰.
@@@@Objective To investigate the risk of hepatotoxicity induced by protein tyrosine kinase inhibitor (TKI) in cancer patients.Methods A search for the related case-control studies on TKI for the treatment of cancer patients was conducted in databases including PubMed ,CNKI,CBM,Wangfang,and search engines such as Google , Baidu.The risk of hepatotoxicity induced by TKI was evaluated .Results A total of 6 case-control studies were included.A Meta-analysis showed that the risk of hepatotoxicity in the TKI group increased significantly compared with placebo group (pooled odds ratio(OR)=6.07,95%confidence interval(CI)=3.06-12.05);Taking AST elevation as an observation index,the pooled analysis suggested that the risk of hepatotoxicity increased significantly in the patients treated with TKI(OR=6.84,95%CI=2.87-16.28).Conclusion The risk of hepatotoxicity increases significantly in cancer patients treated with TKI,which suggests that the real-time detection and observation on the patients′liver function should be performed during the treatment .